Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ERYC 125 vs R-P MYCIN
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Erythromycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking translocation of peptidyl-t RNA. It also activates motilin receptors in the gastrointestinal tract, enhancing gastric motility.
R-P MYCIN is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome, specifically at the 23S r RNA of the peptidyl transferase center. This action blocks the translocation step, thereby preventing the elongation of the peptide chain.
Treatment of infections caused by susceptible strains of microorganisms (e.g., respiratory tract infections, skin infections, pertussis, diphtheria, syphilis),Off-label: Prokinetic agent for gastroparesis, treatment of delayed gastric emptying
Treatment of upper and lower respiratory tract infections,Skin and soft tissue infections,Whooping cough (pertussis),Diphtheria,Chlamydial infections,Legionnaires' disease,Mycoplasma pneumoniae infections,Erythrasma,Intestinal amebiasis,Pelvic inflammatory disease (when penicillin is contraindicated),Off-label: Used for gastric motility stimulation (as a motilin agonist)
250 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day.
Rifampin 600 mg orally once daily or 10 mg/kg intravenously once daily.
1.5-2.0 hours in adults; prolonged in hepatic impairment (up to 5-6 hours) or neonates.
Terminal half-life 2-3 hours; prolonged in renal impairment (up to 6-8 hours in anuria).
Primarily hepatic via cytochrome P450 3A4 (CYP3A4) isoenzyme; undergoes demethylation and hydrolysis; major metabolite is desosamine.
No dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce dose by 50% or extend interval to every 8-12 hours.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min, reduce dose to 300 mg orally once daily. For GFR <10 m L/min, administer 300 mg orally once daily with monitoring.
No FDA boxed warning for ERYC 125.
Erythromycin, including ERYC 125, has not been associated with major congenital malformations in human studies. However, there is a potential increased risk of pyloric stenosis in infants exposed in utero or postnatally. No known teratogenic effects in first trimester; use in pregnancy is generally considered safe when indicated, especially for infections like chlamydia or syphilis.
FDA Pregnancy Category D. First trimester: Avoid due to risk of fetal harm (e.g., skeletal dysplasia, cardiovascular malformations). Second/third trimester: Use only if benefit outweighs risk; may cause fetal renal impairment, oligohydramnios, and neonatal toxicity.
ERYC 125 (erythromycin ethylsuccinate) is a macrolide antibiotic; note that it may prolong QT interval, especially when combined with other QT-prolonging drugs. Avoid use in patients with hepatic impairment or known cholestatic jaundice. Administer on an empty stomach (1 hour before or 2 hours after meals) for optimal absorption, but food does not significantly affect the ethylsuccinate formulation.
R-P MYCIN is a combination of rifampin and pyrazinamide, used for tuberculosis. Monitor for hepatotoxicity; baseline and periodic LFTs required. Rifampin induces CYP450, reducing efficacy of oral contraceptives, warfarin, and antiretrovirals. Pyrazinamide may cause hyperuricemia and gout flares. Administer on empty stomach for better absorption.
No interactions on record
No interactions on record
ERYC 125 and R-P MYCIN are distinct pharmacological agents. ERYC 125 belongs to the Macrolide Antibiotic class and is primarily used for Treatment of infections caused by susceptible strains of microorganisms (e.g., respiratory tract infections, skin infections, pertussis, diphtheria, syphilis)Off-label: Prokinetic agent for gastroparesis, treatment of delayed gastric emptying. R-P MYCIN belongs to the Macrolide Antibiotic class and is primarily used for Treatment of upper and lower respiratory tract infectionsSkin and soft tissue infectionsWhooping cough (pertussis)DiphtheriaChlamydial infectionsLegionnaires' diseaseMycoplasma pneumoniae infectionsErythrasmaIntestinal amebiasisPelvic inflammatory disease (when penicillin is contraindicated)Off-label: Used for gastric motility stimulation (as a motilin agonist). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. ERYC 125 carries a safety status of Category C, whereas R-P MYCIN safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
R-P MYCIN is primarily metabolized by the hepatic cytochrome P450 system, mainly via CYP3A4 isoenzyme. It undergoes demethylation and other oxidative processes. Significant first-pass metabolism occurs, leading to variable bioavailability.
Primarily hepatic metabolism; ~2-5% excreted unchanged in urine, ~15-20% in bile/feces as active drug.
Renal (60-80% unchanged), biliary/fecal (15-20%).
70-90% bound to albumin and alpha-1-acid glycoprotein.
30-40% bound to serum albumin.
0.5-0.9 L/kg; indicates distribution into total body water with some tissue binding.
0.6-1.2 L/kg; increased in extracellular fluid expansion or decreased in dehydration.
Oral: ~35% (acid-labile, enteric-coated).
Oral: 30-40% (due to first-pass metabolism); IV: 100%.
Child-Pugh Class A: no adjustment. Class B: reduce dose by 50%. Class C: reduce dose by 75% or avoid use.
Child-Pugh Class A: standard dosing. Child-Pugh Class B: reduce to 450 mg orally once daily. Child-Pugh Class C: reduce to 300 mg orally once daily or avoid use.
30-50 mg/kg/day orally divided every 6-8 hours; maximum 2 g/day.
Children: 10-20 mg/kg orally once daily, maximum 600 mg/day. For tuberculosis, 10-20 mg/kg orally once daily; for prophylaxis, 15-20 mg/kg orally once daily.
No specific adjustment; monitor for ototoxicity and QT prolongation; consider lower initial dose due to age-related renal decline.
No specific dose adjustment required, but monitor for hepatotoxicity and adjust based on renal function. Consider starting at lower end of dosing range due to age-related decline in organ function.
There is no FDA black box warning for R-P MYCIN.
Grapefruit and grapefruit juice should be avoided as they can increase drug levels and risk of toxicity. Food does not significantly alter absorption of the ethylsuccinate formulation, but taking with a high-fat meal may slightly delay absorption. Avoid alcohol as it may increase risk of hepatotoxicity.
Avoid alcohol. No specific food restrictions, but high-fat meals may delay absorption of rifampin. Maintain adequate hydration to reduce uric acid crystallization risk from pyrazinamide.
Erythromycin is excreted into breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.5. It is considered compatible with breastfeeding by the American Academy of Pediatrics, but may increase the risk of pyloric stenosis in neonates. Monitor for gastrointestinal symptoms in the infant.
Not recommended during breastfeeding. M/P ratio unknown; potential for infant toxicity (e.g., nephrotoxicity, ototoxicity).
No specific dose adjustment is required for pregnancy based on pharmacokinetic changes. However, erythromycin has reduced plasma concentrations in late pregnancy due to increased volume of distribution and clearance, but no dose adjustment is recommended. Standard dosing is used.
No standard dose adjustment; increased volume of distribution and GFR may reduce serum concentrations. Monitor trough levels closely; dose adjustment may be needed to maintain therapeutic levels.
Take exactly as prescribed; do not skip doses or stop early even if you feel better.,Take this medication on an empty stomach, at least 1 hour before or 2 hours after a meal.,Avoid grapefruit and grapefruit juice while taking this medicine.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, severe stomach pain.,Notify your doctor immediately if you experience irregular heartbeat, fainting, or severe diarrhea.,Complete the full course to prevent antibiotic resistance.
Take this medication exactly as prescribed, usually daily for the first 2 months of TB treatment.,Take on an empty stomach, 1 hour before or 2 hours after meals.,May discolor urine, sweat, sputum, or tears orange-red (harmless).,Avoid alcohol completely due to increased risk of liver damage.,Use non-hormonal contraception; rifampin reduces birth control pill effectiveness.,Report signs of liver injury: yellowing skin/eyes, dark urine, abdominal pain, nausea/vomiting, unusual tiredness.,Report joint pain or swelling (pyrazinamide may raise uric acid).